Next Article in Journal
Advancements in Circulating Tumor Cell Research: Bridging Biology and Clinical Applications
Previous Article in Journal
Clinical Workflow of Cone Beam Computer Tomography-Based Daily Online Adaptive Radiotherapy with Offline Magnetic Resonance Guidance: The Modular Adaptive Radiotherapy System (MARS)
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Cancers
Volume 16
Issue 6
10.3390/cancers16061211
cancers-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Correction to Cancers 2023, 15(10), 2796.
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Correction

Correction: Casili et al. Therapeutic Potential of BAY-117082, a Selective NLRP3 Inflammasome Inhibitor, on Metastatic Evolution in Human Oral Squamous Cell Carcinoma (OSCC). Cancers 2023, 15, 2796

by
Giovanna Casili
1,†,
Sarah Adriana Scuderi
1,†,
Marika Lanza
1,
Alessia Filippone
1,
Deborah Mannino
1,
Raffaella Giuffrida
2,
Cristina Colarossi
2,
Marzia Mare
2,
Anna Paola Capra
1,
Federica De Gaetano
1,
Marco Portelli
3,
Angela Militi
1,
Salvatore Cuzzocrea
1,
Irene Paterniti
1,* and
Emanuela Esposito
1
1
Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, Viale Ferdinando Stagno D’Alcontres, 31, 98166 Messina, Italy
2
IOM Ricerca, Via Penninazzo 11, 95029 Viagrande Catania, Italy
3
Department of Biomedical and Dental Science, Morphological and Functional Images, University of Messina, Via Consolare Valeria, 98125 Messina, Italy
*
Author to whom correspondence should be addressed.
†
These authors contributed equally to this work.
Cancers 2024, 16(6), 1211; https://0-doi-org.brum.beds.ac.uk/10.3390/cancers16061211
Submission received: 7 December 2023 / Accepted: 16 January 2024 / Published: 20 March 2024
(This article belongs to the Section Cancer Biomarkers)
Browse Figure
Review Reports Versions Notes
In the original publication [1], there was a mistake in Figure 4L as published. Figure 4I and Figure 4L were the same image, displayed with slightly different brightnesses. The corrected Figure 4 appears below.
The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.

Reference

  1. Casili, G.; Scuderi, S.A.; Lanza, M.; Filippone, A.; Mannino, D.; Giuffrida, R.; Colarossi, C.; Mare, M.; Capra, A.P.; De Gaetano, F.; et al. Therapeutic Potential of BAY-117082, a Selective NLRP3 Inflammasome Inhibitor, on Metastatic Evolution in Human Oral Squamous Cell Carcinoma (OSCC). Cancers 2023, 15, 2796. [Google Scholar] [CrossRef] [PubMed]
Cancers 16 01211 g001
Figure 4. BAY-117082 treatment modulated the metastasis process in the lymph node, lung, and spleen. Histological analysis revealed that the treatment with BAY-117082 at doses of 2.5 and 5 mg/kg was able to reduce the degree of metastasis in the lymph node (C,D,M), lung (G,H,N), and spleen (K,L,O) in the C group compared with the OSCC group (B,F,J). (A,E,I) Control groups in the lymph node, lung, and spleen. Data are representative of at least three independent experiments. ND, not designed. *** p < 0.001 vs. sham; ### p < 0.001 and vs. ## p < 0.01 OSCC.
Figure 4. BAY-117082 treatment modulated the metastasis process in the lymph node, lung, and spleen. Histological analysis revealed that the treatment with BAY-117082 at doses of 2.5 and 5 mg/kg was able to reduce the degree of metastasis in the lymph node (C,D,M), lung (G,H,N), and spleen (K,L,O) in the C group compared with the OSCC group (B,F,J). (A,E,I) Control groups in the lymph node, lung, and spleen. Data are representative of at least three independent experiments. ND, not designed. *** p < 0.001 vs. sham; ### p < 0.001 and vs. ## p < 0.01 OSCC.
Cancers 16 01211 g001
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Casili, G.; Scuderi, S.A.; Lanza, M.; Filippone, A.; Mannino, D.; Giuffrida, R.; Colarossi, C.; Mare, M.; Capra, A.P.; De Gaetano, F.; et al. Correction: Casili et al. Therapeutic Potential of BAY-117082, a Selective NLRP3 Inflammasome Inhibitor, on Metastatic Evolution in Human Oral Squamous Cell Carcinoma (OSCC). Cancers 2023, 15, 2796. Cancers 2024, 16, 1211. https://0-doi-org.brum.beds.ac.uk/10.3390/cancers16061211

AMA Style

Casili G, Scuderi SA, Lanza M, Filippone A, Mannino D, Giuffrida R, Colarossi C, Mare M, Capra AP, De Gaetano F, et al. Correction: Casili et al. Therapeutic Potential of BAY-117082, a Selective NLRP3 Inflammasome Inhibitor, on Metastatic Evolution in Human Oral Squamous Cell Carcinoma (OSCC). Cancers 2023, 15, 2796. Cancers. 2024; 16(6):1211. https://0-doi-org.brum.beds.ac.uk/10.3390/cancers16061211

Chicago/Turabian Style

Casili, Giovanna, Sarah Adriana Scuderi, Marika Lanza, Alessia Filippone, Deborah Mannino, Raffaella Giuffrida, Cristina Colarossi, Marzia Mare, Anna Paola Capra, Federica De Gaetano, and et al. 2024. "Correction: Casili et al. Therapeutic Potential of BAY-117082, a Selective NLRP3 Inflammasome Inhibitor, on Metastatic Evolution in Human Oral Squamous Cell Carcinoma (OSCC). Cancers 2023, 15, 2796" Cancers 16, no. 6: 1211. https://0-doi-org.brum.beds.ac.uk/10.3390/cancers16061211

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop